Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConduit Hldg Regulatory News (CRE)

Share Price Information for Conduit Hldg (CRE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 502.00
Bid: 500.00
Ask: 502.00
Change: 7.00 (1.41%)
Spread: 2.00 (0.40%)
Open: 492.00
High: 502.00
Low: 492.00
Prev. Close: 495.00
CRE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of The Corkery Group

30 Nov 2011 07:01

RNS Number : 0163T
Creston PLC
30 November 2011
 



30 November 2011

Creston plc

('Creston' or the 'Group')

Acquisition of The Corkery Group

Cooney Waters LLC ('Cooney/Waters'), a subsidiary of Creston plc ('Creston' or the 'Group'), the Insight and Communications Group, today announces the acquisition of 100 per cent of the share capital of The Corkery Group, a New York based full service health and medical public relations company specialising in product and issues communications for the world's leading health organisations. Total initial cash payments amounting to US$6.0 million (£3.8 million) will be payable.

 

As well as being immediately earnings enhancing, the acquisition of The Corkery Group strengthens the Health division and complements Cooney/Waters, the US healthcare communications specialist that was acquired by Creston last year. Following today's announcement, The Corkery Group will operate as a 100 per cent subsidiary and trading division of the Cooney/Waters Group.

 

Under the terms of the Cooney/Waters acquisition, Creston agreed a deferred consideration based on the future profit before interest and tax of the acquired businesses (the 'C/W Deferred Consideration'), of which Lenore Cooney was the sole beneficiary. As The Corkery Group will become a 100 per cent subsidiary of Cooney/Waters and be fully integrated with immediate effect, Lenore Cooney has agreed that David Corkery, The Corkery Group's founder, will become a named recipient of 47 per cent of any future payments made under the C/W Deferred Consideration. There are no changes to the maximum value of potential payments made under the C/W Deferred Consideration, which is capped at US$21 million.

 

Founded in 1998, The Corkery Group employs 25 staff and is focused on long-term relationships with a diverse mix of clients including: International agencies, US government agencies, pharmaceutical and bio-technology companies and non-profit organisations. The Corkery Group's healthcare industry expertise spans scientific, policy and product communications, media relations, digital media, executive support and crisis management. Current clients include: American Society of Clinical Oncology, Gilead Sciences and the U.S. Centers for Disease Control and Prevention.

 

Following the acquisition, The Corkery Group will continue to benefit from the experience and expertise of David Corkery, who will continue as a Senior Advisor. Additionally, senior members of The Corkery Group's existing management team, Karen O'Malley (President of The Corkery Group) and Greg Lugliani (Executive Vice President), will join the Cooney/Waters Group's operating board.

 

Through adding new clients and complementary expertise and talent to the Group, as well sharing best practice and knowhow, we believe there are many synergy benefits to be leveraged by the wider Group as a result of this acquisition. Both companies will be re-located to one central location in 2012.

 

For the financial year ended 31 December 2010, The Corkery Group reported revenues of US$9.9 million (£6.4 million) and a profit before taxation of US$0.3 million (£0.2 million) - pre any shareholder bonus dividends profit before tax was US$3.5 million (£2.2 million). As at 31 December 2010 The Corkery Group had reported gross assets of US$2.0 million (£1.3 million). For the nine months ending 30 September 2011, The Corkery Group had unaudited revenues of US$6.3 million (£4.0 million) and pre any shareholder bonus dividends a profit before interest and tax of $1.9 million (£1.2 million). This is a lower financial performance than the prior year, due to the company's resignation of a client in 2010.

 

Commenting on the acquisition, Don Elgie, Group Chief Executive of Creston plc, said: "The Corkery Group is an excellent business with a strong track record of individual account growth and an attractive client list. The Corkery Group and Cooney/Waters are well known to one another, their cultures are similar and I am confident the increased critical mass of the combined business will benefit both operations going forward."

 

 

 

For further information please contact:

 

Creston plc

+ 44 (0)20 7930 9757

Don Elgie, Group Chief Executive

Barrie Brien, COO/CFO

M:Communications

+44 (0)20 7920 2339

Elly Williamson

 

 

 

About Creston plc

Creston plc (LSE: CRE) is a marketing services company focused on insight-led communications. The Group delivers a range of marketing services, including digital marketing, market research, health communications, public relations, direct marketing, advertising and brand consultancy to a broad spectrum of blue-chip clients. All our companies share a common commitment to understanding, influencing and inspiring consumers on behalf of our clients and to creating value through innovative collaborative working. www.creston.com

 

 

About The Corkery Group

The Corkery Group is a full-service public relations firm specialising in health and medical communications. Internationally recognised for its expertise in issue-oriented and product communications, The Corkery Group works with the world's leading health organisations. www.corkerygroup.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQFELEEUFFSESF
Date   Source Headline
25th Apr 20244:11 pmRNSHolding(s) in Company
19th Apr 20247:00 amRNSHolding(s) in Company
18th Apr 20247:00 amRNSHolding(s) in Company
12th Apr 20247:00 amRNSNotice of AGM
12th Apr 20247:00 amRNSDirector/PDMR Shareholding
8th Apr 20244:34 pmRNSDirector/PDMR Shareholding
4th Apr 20243:52 pmRNSDirector/PDMR Shareholding
28th Mar 20243:53 pmRNSDirector/PDMR Shareholding
27th Mar 20247:00 amRNSDirector/PDMR Shareholding
25th Mar 20244:49 pmRNSDirector/PDMR Shareholding
25th Mar 20244:49 pmRNSDirector/PDMR Shareholding
25th Mar 20244:48 pmRNSDirector/PDMR Shareholding
25th Mar 20244:48 pmRNSDirector/PDMR Shareholding
12th Mar 20243:11 pmRNSHolding(s) in Company
7th Mar 20245:52 pmRNSPurchase of Shares by Employee Benefit Trust
6th Mar 20243:53 pmRNSPurchase of Shares by Employee Benefit Trust
6th Mar 20247:00 amRNSHolding(s) in Company
5th Mar 20244:48 pmRNSPurchase of Shares by Employee Benefit Trust
4th Mar 20243:58 pmRNSPurchase of Shares by Employee Benefit Trust
1st Mar 20244:00 pmRNSPurchase of Shares by Employee Benefit Trust
28th Feb 20241:40 pmRNSAnnual Financial Report
28th Feb 20247:00 amRNSPurchase of Shares by Employee Benefit Trust
28th Feb 20247:00 amRNSHolding(s) in Company
26th Feb 20245:44 pmRNSPurchase of Shares by Employee Benefit Trust
26th Feb 20247:00 amRNSPurchase of Shares by Employee Benefit Trust
21st Feb 20247:00 amRNSAppointment of Senior Independent Director
21st Feb 20247:00 amRNSPreliminary results for the year ended 31/12/2023
13th Feb 20247:00 amRNSNotice of Full Year 2023 Trading Update
29th Jan 20247:00 amRNSPerformance Update
25th Jan 20247:00 amRNSJanuary 2024 Trading Update
15th Jan 20247:00 amRNSNotice of 1 January 2024 Renewals Trading Update
14th Dec 20235:39 pmRNSDirector/PDMR Shareholding
8th Dec 20233:45 pmRNSPurchase of Shares by Employee Benefit Trust
7th Dec 20232:22 pmRNSPurchase of Shares by Employee Benefit Trust
6th Dec 20232:52 pmRNSPurchase of Shares by Employee Benefit Trust
6th Dec 20237:00 amRNSPurchase of Shares by Employee Benefit Trust
5th Dec 20233:46 pmRNSPurchase of Shares by Employee Benefit Trust
1st Dec 20235:28 pmRNSPurchase of Shares by Employee Benefit Trust
30th Nov 20233:28 pmRNSPurchase of Shares by Employee Benefit Trust
29th Nov 20233:51 pmRNSPurchase of Shares by Employee Benefit Trust
29th Nov 20237:00 amRNSHolding(s) in Company
28th Nov 20234:41 pmRNSPurchase of Shares by Employee Benefit Trust
27th Nov 20233:17 pmRNSPurchase of Shares by Employee Benefit Trust
24th Nov 20232:02 pmRNSPurchase of Shares by Employee Benefit Trust
23rd Nov 20234:25 pmRNSPurchase of Shares by Employee Benefit Trust
22nd Nov 20235:06 pmRNSPurchase of Shares by Employee Benefit Trust
17th Nov 20234:20 pmRNSPurchase of Shares by Employee Benefit Trust
8th Nov 20237:00 amRNSDirectorate Change
8th Nov 20237:00 amRNSThird Quarter 2023 Trading Update
26th Oct 20237:00 amRNSNotice of Q3 2023 Trading Update and Webcast

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.